Skip to main content
. 2021 Jan 15;39(7):723–733. doi: 10.1200/JCO.20.01605

FIG 4.

FIG 4.

Patients on treatment with first treatment-related select AE by yeara,b. Median (range) nivolumab treatment duration: 2.8 (0-76.2 +) months. aIncludes events of any grade reported between the first dose and 30 days after the last dose of trial therapy; bSelect AEs were events with a potential immunological cause. AE, adverse event; No., number.